Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Evommune
Biotech
Evommune prices IPO amid government shutdown
Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price between $15 and $17 per share.
Gabrielle Masson
Oct 30, 2025 12:34pm
Inflammation biotech Evommune eyes IPO to fund dermatitis trials
Oct 10, 2025 6:35am
Canadian VC Amplitude unveils $192M biotech fund
May 29, 2024 10:30am
Pivotal bioVenture Partners unveils $389M fund
Dec 18, 2023 7:00am
Evommune drops IRAK4 inhibitor on phase 2 dermatitis data
Sep 27, 2023 10:30am
